SOADOR
PLX icon

State of Alaska Department of Revenue’s Protalix BioTherapeutics PLX Stock Holding History

State of Alaska Department of Revenue’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50K Hold
21,831
– – ﹤0.01% 1925
2026
Q1 		$47K Hold
21,831
– – ﹤0.01% 1922
2025
Q4 		$39K Buy
+21,831
New +$44.6K ﹤0.01% 1959

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MSFS
Main Street Financial Solutions Newtown, Pennsylvania $1.56B AUM 24.84% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State of Alaska Department of Revenue's PLX Position: Q2 2026 in Review

State of Alaska Department of Revenue held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 21,831 shares worth $50K. The position accounts for ﹤0.01% of the portfolio, ranked #1925.

State of Alaska Department of Revenue first reported a position in PLX in Q4 2025 and has held it in 3 quarters since. 62 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • State of Alaska Department of Revenue held 21,831 shares of Protalix BioTherapeutics worth $50K as of Q2 2026.
  • State of Alaska Department of Revenue left its Protalix BioTherapeutics share count unchanged in Q2 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of State of Alaska Department of Revenue's portfolio in Q2 2026, its #1925 holding.
  • State of Alaska Department of Revenue first reported a position in Protalix BioTherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 62 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on State of Alaska Department of Revenue's 13F filing for Q2 2026, filed 20 Jul 2026.